In July 2016, Merck shared the following update on progress in achieving its Family Planning 2020 commitment during the 2015-2016 time period (commitment included for reference below).

FINANCIAL UPDATES

- Merck/MSD remains committed to honoring its access pricing for IMPLANON® and IMPLANON NXT®—its single-rod, long-acting, reversible contraceptive implants—in FP2020 focus countries for an additional five years through 2023.
The following text is the commitment made by Merck in November 2015 to Family Planning 2020. To review the commitment online, please visit: http://www.familyplanning2020.org/merck.

FINANCIAL COMMITMENTS

Merck, known as MSD outside the United States and Canada, commits to extending access pricing for IMPLANON® and IMPLANON NXT®—its single-rod, long-acting, reversible contraceptive implants—in FP2020 focus countries for an additional five years through 2023.

This builds on Merck’s original announcement in May 2013 to reduce the cost of its implants by approximately 50 percent for six years, through 2018.

Since May 2013, the number of IMPLANON® and IMPLANON NXT® implants provided in targeted countries has doubled, bringing greater choice to millions of women in some of the world’s poorest regions. Merck continues to work with the Bill & Melinda Gates Foundation and other FP2020 partners in implementing the IMPLANON® Access Program.